IRG1–Itaconate Axis Protects From Cholesterol-Induced Inflammation and Atherosclerosis
- Description
Therapeutic approaches to reverse atherosclerotic inflammation are needed to address the rising global burden of cardiovascular disease (CVD). This study investigated therapeutic potential of the enzyme immune responsive gene 1 (IRG1) and its immunomodulatory product, itaconate for atherosclerosis in humans and mice. To investigate the expression of IRG1 in human atherosclerosis, single-cell RNA sequencing (scRNA-seq) of human coronary fibroatheromas and paired coronary adaptive intimal thickening was performed from the same patients. In addition, to determine how 4-OI affects the transcriptional signature of human immune cells exposed to CVD plasma, scRNA-seq was performed on treated human primary peripheral blood mononuclear cells. To examine how Irg1-deficiency alters the transcriptional signatures and dynamics of immune cell populations in plaque, scRNA-seq was performed on CD45+ cells isolated from the aortic arches of WT or Irg1–/– atherosclerotic mice.
- Geographic Coverage
-
New York (State) - New York City
Access
- Restrictions
-
Free to All
- Instructions
- Single-cell RNA sequencing data have been deposited in Gene Expression Omnibus (GEO).
- Grant Support
-
NFL-2020-218415/Chan Zuckerberg Initiative19CDA34630066/American Heart Association20SFRN35210252/American Heart Association23SCEFIA1153739/American Heart Association915560/American Heart AssociationMFE-176524/Canadian Institutes of Health Research23POST1029885/American Heart Association